Literature DB >> 21835473

Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva.

Ludwig M Heindl1, Carmen Hofmann-Rummelt, Werner Adler, Jacobus J Bosch, Leonard M Holbach, Gottfried O H Naumann, Friedrich E Kruse, Claus Cursiefen.   

Abstract

PURPOSE: To evaluate whether tumor-associated lymphangiogenesis contributes to prognosis of conjunctival malignant melanomas and to study its association with other tumor characteristics.
DESIGN: Nonrandomized, retrospective case series. PARTICIPANTS: A total of 109 consecutive patients with primary conjunctival malignant melanoma.
METHODS: Proliferating lymphatic vessels were identified immunohistochemically using lymphatic vascular endothelial hyaluronan receptor-1 and podoplanin as specific lymphatic endothelial markers and Ki-67 as proliferation marker. Baseline tumor characteristics included tumor location, tumor thickness, tumor diameter, tumor origin, and tumor growth pattern. Kaplan-Meier and Cox regression analyses of the risk of local recurrence, lymphatic spread, distant metastasis, and melanoma-related death were performed. MAIN OUTCOME MEASURES: Intratumoral lymphatic vascular density and its association with tumor characteristics and recurrence-free, lymphatic spread-free, distant metastasis-free, and melanoma-specific survival.
RESULTS: Intratumoral and peritumoral proliferating lymphatic vessels could be detected in all of the 109 conjunctival melanoma samples. High intratumoral lymphatic density was significantly associated with palpebral tumor location (P<0.001), greater tumor thickness (P<0.001), larger tumor diameter (P = 0.001), tumor origin de novo (P = 0.002), and nodular tumor growth pattern (P = 0.037). Patients with high intratumoral lymphatic density revealed significantly lower recurrence-free, lymphatic spread-free, distant metastasis-free, and melanoma-specific survival rates (P<0.001 for all). By multivariate Cox regression, factors predictive of local recurrence included palpebral tumor location (hazard ratio [HR] 2.66, P = 0.014), large tumor diameter (HR 5.48, P<0.001), and high intratumoral lymphatic density (HR 2.48, P = 0.043); factors predictive of lymphatic spread included palpebral tumor location (HR 4.13, P = 0.009), high tumor thickness (HR 12.17, P<0.001), and high intratumoral lymphatic density (HR 6.79, P = 0.019); factors predictive of distant metastasis included palpebral tumor location (HR 7.63, P<0.001), high tumor thickness (HR 8.60, P<0.001), large tumor diameter (HR 0.30, P = 0.029), and high intratumoral lymphatic density (HR 8.90, P = 0.047); and factors predictive of melanoma-related death included palpebral tumor location (HR 7.74, P<0.001), high tumor thickness (HR 10.88, P<0.001), large tumor diameter (HR 0.28, P = 0.018), and, with borderline significance, high intratumoral lymphatic density (HR 8.46, P = 0.052).
CONCLUSIONS: Tumor-associated lymphangiogenesis seems to be associated with an increased risk of local recurrence, lymphatic spread, distant metastasis, and melanoma-related death in patients with conjunctival malignant melanomas. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835473     DOI: 10.1016/j.ophtha.2011.05.025

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

1.  [Conjunctival melanoma: a systemic disease: Novel surgical and adjuvant therapies].

Authors:  L M Heindl; C Cursiefen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

Review 2.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

3.  Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis.

Authors:  Rita Pinto-Proença; Mariana Santos; Cristina Fonseca; Júlia Fernandes; Maria Filomena Gaspar; Rui Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-02       Impact factor: 3.117

4.  [Conjunctival melanoma : Standard operating procedures in diagnosis, treatment and follow-up care].

Authors:  Jan-Peter Glossmann; Nicole Skoetz; Barbara Starbatty; Martina Bischoff; Serge Leyvraz; Henrike Westekemper; Ludwig M Heindl
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

Review 5.  Ocular melanoma: an overview of the current status.

Authors:  Predrag Jovanovic; Marija Mihajlovic; Jasmina Djordjevic-Jocic; Slobodan Vlajkovic; Sonja Cekic; Vladisav Stefanovic
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

Review 6.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

7.  Ocular melanoma.

Authors:  Bertil E Damato; Sarah E Coupland
Journal:  Saudi J Ophthalmol       Date:  2012-04

Review 8.  [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].

Authors:  L M Heindl; K R Koch; M Schlaak; C Mauch; C Cursiefen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

9.  Epidermal Growth Factor Is Increased in Conjunctival Malignant Melanoma.

Authors:  Vinodh Kakkassery; Christoph Wirtz; Marc Schargus; Salvatore Grisanti; Aysegül Tura; Mahdy Ranjbar; H Burkhard Dick; Sabrina Reinehr; Stephanie C Joachim
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

10.  Conjunctival Melanoma Angiotropic Microsatellitosis: A Mechanism of Local Extravascular Migratory Metastasis.

Authors:  Jose J Echegaray; Gabrielle Yeaney; Rachel Chen; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2020-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.